Colby Pharmaceutical Company is developing the next generation of safe and effective products and delivery technologies for inflammatory (CPC-551), immune (ILNI™ platform), and pain (CPC-123, CPC-111) conditions in large (multi-billion dollar) global markets with existing unmet medical needs. Colby products are designed to provide patients faster acting, longer lasting, dose sparing, safer/non-toxic/lower-risk, higher efficacy and more cost effective interventional treatments.
Disclaimer and Forward-Looking Statements
This web site contains "forward-looking statements," including statements about the Company's growth, future operating results, discovery and development of products, strategic alliances and intellectual property.Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, compensation arrangements, financing needs, plans or intentions relating to acquisitions, business trends and other information that is not historical information. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery, pre-clinical and clinical development programs; failure to obtain grants; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; difficulties or delays in obtaining regulatory approvals to market products and services resulting from the Company's development efforts; product withdrawals; competitive factors; difficulties or delays in commercialization of Company's products; and the requirement for substantial funding to conduct research and development and to expand commercialization activities.